46 related articles for article (PubMed ID: 7506428)
21. Fc gamma receptor II (CD32) on malignant B cells influences modulation induced by anti-CD19 monoclonal antibody.
Vervoordeldonk SF; Merle PA; van Leeuwen EF; van der Schoot CE; von dem Borne AE; Slaper-Cortenbach IC
Blood; 1994 Mar; 83(6):1632-9. PubMed ID: 7510146
[TBL] [Abstract][Full Text] [Related]
22. Selective increase of alternatively spliced Lck transcripts from the proximal promotor in hematopoietic malignancies.
Rouer E; Dreyfus F; Melle J; Ribrag V; Benarous R
Leukemia; 1993 Feb; 7(2):246-50. PubMed ID: 8426478
[TBL] [Abstract][Full Text] [Related]
23. Activation of Src-like p56/p53lyn tyrosine kinase by ionizing radiation.
Kharbanda S; Yuan ZM; Rubin E; Weichselbaum R; Kufe D
J Biol Chem; 1994 Aug; 269(32):20739-43. PubMed ID: 8051175
[TBL] [Abstract][Full Text] [Related]
24. Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in patients with B-lineage lymphoid malignancies.
Chen CL; Levine A; Rao A; O'Neill K; Messinger Y; Myers DE; Goldman F; Hurvitz C; Casper JT; Uckun FM
J Clin Pharmacol; 1999 Dec; 39(12):1248-55. PubMed ID: 10586390
[TBL] [Abstract][Full Text] [Related]
25. Large scale manufacturing of B43(anti-CD19)-genistein for clinical trials in leukemia and lymphoma.
Myers DE; Sicheneder A; Clementson D; Dvorak N; Venkatachalam T; Sev AR; Chandan-Langlie M; Uckun FM
Leuk Lymphoma; 1998 Apr; 29(3-4):329-38. PubMed ID: 9684930
[TBL] [Abstract][Full Text] [Related]
26. Heterogeneity of the inhibitory effects of IL-4 in two novel B lineage acute lymphoblastic leukemia cell lines.
Renard N; Harada N; Callet-Bauchu E; Miyajima A; Duvert V; Banchereau J; Saeland S
Leuk Res; 1997; 21(11-12):1037-46. PubMed ID: 9444937
[TBL] [Abstract][Full Text] [Related]
27. In vivo toxicity and pharmacokinetic features of B43(Anti-CD19)-Genistein immunoconjugate.
Ek O; Yanishevski Y; Zeren T; Waurzyniak B; Gunther R; Chelstrom L; Chandan-Langlie M; Schneider E; Myers DE; Evans W; Uckun FM
Leuk Lymphoma; 1998 Jul; 30(3-4):389-94. PubMed ID: 9713969
[TBL] [Abstract][Full Text] [Related]
28. Plasticity of lineage switch in B-ALL allows for successful rechallenge with CD19-directed immunotherapy.
Lee BM; Summers C; Chisholm KM; Bohling SD; Leger KJ; Gardner R; Annesley C; Lamble AJ
Blood Adv; 2023 Jun; 7(12):2825-2830. PubMed ID: 36763522
[No Abstract] [Full Text] [Related]
29. Anti-CD19 resistance can "stem" from progenitors.
Shah NN; Fry TJ
Blood; 2017 Nov; 130(18):1961-1963. PubMed ID: 29097371
[TBL] [Abstract][Full Text] [Related]
30. In vivo toxicity, pharmacokinetic features, and immunogenicity of B43(Anti-CD19)-genistein immunoconjugate in mice and non-human primates.
Myers DE; Uckun FM
J Med Food; 1999; 2(3-4):173-5. PubMed ID: 19281372
[No Abstract] [Full Text] [Related]
31. Is the tyrosine kinase B receptor a target for preventing epilepsy?
Swanwick CC; Kapur J
Epilepsy Curr; 2005; 5(1):7-10. PubMed ID: 16059446
[No Abstract] [Full Text] [Related]
32. Identification of Biomarkers for Cervical Cancer Radiotherapy Resistance Based on RNA Sequencing Data.
Feng Y; Wang Z; Yang N; Liu S; Yan J; Song J; Yang S; Zhang Y
Front Cell Dev Biol; 2021; 9():724172. PubMed ID: 34414195
[TBL] [Abstract][Full Text] [Related]
33. Potentially autoreactive naturally occurring transitional T3 B lymphocytes exhibit a unique signaling profile.
Liubchenko GA; Appleberry HC; Holers VM; Banda NK; Willis VC; Lyubchenko T
J Autoimmun; 2012 Jun; 38(4):293-303. PubMed ID: 22365785
[TBL] [Abstract][Full Text] [Related]
34. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor.
Uckun FM; Messinger Y; Chen CL; O'Neill K; Myers DE; Goldman F; Hurvitz C; Casper JT; Levine A
Clin Cancer Res; 1999 Dec; 5(12):3906-13. PubMed ID: 10632319
[TBL] [Abstract][Full Text] [Related]
35. Signaling through the EBV/C3d receptor (CR2, CD21) in human B lymphocytes: activation of phosphatidylinositol 3-kinase via a CD19-independent pathway.
Bouillie S; Barel M; Frade R
J Immunol; 1999 Jan; 162(1):136-43. PubMed ID: 9886379
[TBL] [Abstract][Full Text] [Related]
36. The tyrosine kinase lck is required for CD95-independent caspase-8 activation and apoptosis in response to ionizing radiation.
Belka C; Marini P; Lepple-Wienhues A; Budach W; Jekle A; Los M; Lang F; Schulze-Osthoff K; Gulbins E; Bamberg M
Oncogene; 1999 Sep; 18(35):4983-92. PubMed ID: 10490833
[TBL] [Abstract][Full Text] [Related]
37. Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2.
Deans JP; Schieven GL; Shu GL; Valentine MA; Gilliland LA; Aruffo A; Clark EA; Ledbetter JA
J Immunol; 1993 Nov; 151(9):4494-504. PubMed ID: 7691952
[TBL] [Abstract][Full Text] [Related]
38. The tyrosine kinase Lck is involved in regulation of mitochondrial apoptosis pathways.
Belka C; Gruber C; Jendrossek V; Wesselborg S; Budach W
Oncogene; 2003 Jan; 22(2):176-85. PubMed ID: 12527887
[TBL] [Abstract][Full Text] [Related]
39. Engagement of the CD19 receptor on human B-lineage leukemia cells activates LCK tyrosine kinase and facilitates radiation-induced apoptosis.
Waddick KG; Chae HP; Tuel-Ahlgren L; Jarvis LJ; Dibirdik I; Myers DE; Uckun FM
Radiat Res; 1993 Dec; 136(3):313-9. PubMed ID: 7506428
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
